ArticleAJOG global reports2025
Long-acting pre-exposure prophylaxis preferences among pregnant and postpartum women in Kenya: results from a discrete choice experiment.
Article in AJOG global reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heterogeneity in preferences for HIV prevention service delivery among women of reproductive age in western Kenya: a latent class analysis.Frontiers in global women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: New long-acting HIV pre-exposure prophylaxis (LA-PrEP) methods may address adherence barriers during pregnant and postpartum periods, when HIV risk is elevated. Understanding their preferences for LA-PrEP is essential for person-centered HIV prevention in maternal and child health (MCH) systems, yet evidence on preferred attributes is limited. Objective: To estimate pregnant and postpartum women's preferred PrEP attributes using a discrete choice experiment (DCE) at important timepoints in the perinatal period. Study design: From February 2023 to July 2024, we conducted a DCE among 513 HIV-negative pregnant and postpartum women taking daily oral PrEP in Kisumu and Siaya, Kenya, enrolled between 24-32 weeks gestation and a high HIV risk score. Participants completed the DCE with 12 choice sets at their third antepartum (median gestational age: 37.0 weeks) and/or 6-month postpartum visits. Attributes included effectiveness, form and dosing, safety data, side effects, collection place, cost, and multipurpose prevention (postpartum only). We fit effects-coded choice data to a conditional logit model, latent class analysis (LCA) for preference heterogeneity, and univariate multinomial logistic regressions to predict class membership by individual characteristics. Results: A total of 513 women completed the DCE at least once (151 at third antepartum, 509 at 6-month postpartum). Every 2-month injections were strongly preferred, showing the highest positive preference weight (pregnant: 1.22, 95% CI: 1.12-1.33; postpartum: 1.24, 95% CI: 1.18-1.30). Four latent classes emerged: "Flexible PrEP Adopters" (37.2%), "Safe and Effective Injection Preference" (16.5%), "Strong Injection Preference" (37.7%), and "Oral PrEP Preference" (8.6%). Higher parity was associated with lower odds of membership in "Flexible PrEP Adopters" (OR=0.6, 95% CI: 0.4-0.8, Conclusions: Strong preferences for every 2-month injectables emphasize the need to prioritize LA-PrEP in this population. ANC settings can support diverse PrEP preference profiles with tailored counseling to account for individual preferences, PrEP experience, and obstetric history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.